aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma (Nasdaq: ATYR), a clinical stage biotechnology company, has announced its participation in the Leerink Partners Global Healthcare Conference in Miami, FL, scheduled for March 9-12, 2025. Dr. Sanjay S. Shukla, President and CEO, will present in a fireside chat format on Monday, March 10, 2025, at 1:40pm EDT.
The company, which focuses on developing first-in-class medicines from its proprietary tRNA synthetase platform, will make the presentation available via webcast on their investor website, with a replay accessible for 90 days afterward. Management will also conduct one-on-one meetings with registered conference attendees.
aTyr specializes in translating tRNA synthetase biology into therapies for fibrosis and inflammation. Their lead candidate, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The company's platform focuses on uncovering signaling pathways through domains derived from all 20 tRNA synthetases.
aTyr Pharma (Nasdaq: ATYR), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione alla Leerink Partners Global Healthcare Conference a Miami, FL, programmata per il 9-12 marzo 2025. Il Dr. Sanjay S. Shukla, Presidente e CEO, presenterà in un formato di chat informale lunedì 10 marzo 2025, alle 13:40 EDT.
L'azienda, che si concentra sullo sviluppo di farmaci innovativi dalla sua piattaforma proprietaria di tRNA sintetasi, renderà disponibile la presentazione tramite webcast sul loro sito web per gli investitori, con una registrazione accessibile per 90 giorni dopo. La direzione condurrà anche incontri individuali con i partecipanti registrati alla conferenza.
aTyr si specializza nella traduzione della biologia della tRNA sintetasi in terapie per la fibrosi e l'infiammazione. Il loro candidato principale, efzofitimod, è un immunomodulatore biologico di prima classe in fase di sviluppo per il trattamento delle malattie polmonari interstiziali. La piattaforma dell'azienda si concentra sull'individuazione delle vie di segnalazione attraverso domini derivati da tutte le 20 tRNA sintetasi.
aTyr Pharma (Nasdaq: ATYR), una empresa biotecnológica en etapa clínica, ha anunciado su participación en la Leerink Partners Global Healthcare Conference en Miami, FL, programada para el 9-12 de marzo de 2025. El Dr. Sanjay S. Shukla, Presidente y CEO, presentará en un formato de charla informal el lunes 10 de marzo de 2025, a la 1:40 p.m. EDT.
La empresa, que se centra en el desarrollo de medicamentos innovadores a partir de su plataforma propietaria de tRNA sintetasa, hará disponible la presentación a través de un webcast en su sitio web para inversores, con una repetición accesible durante 90 días después. La dirección también llevará a cabo reuniones individuales con los asistentes registrados a la conferencia.
aTyr se especializa en traducir la biología de la tRNA sintetasa en terapias para la fibrosis y la inflamación. Su candidato principal, efzofitimod, es un inmunomodulador biológico de primera clase que se está desarrollando para el tratamiento de enfermedades pulmonares intersticiales. La plataforma de la empresa se centra en descubrir vías de señalización a través de dominios derivados de las 20 tRNA sintetasas.
aTyr Pharma (Nasdaq: ATYR), 임상 단계의 생명공학 회사가 2025년 3월 9일부터 12일까지 플로리다주 마이애미에서 열리는 Leerink Partners Global Healthcare Conference에 참여한다고 발표했습니다. 산제이 S. 슈클라 박사, 사장 겸 CEO는 2025년 3월 10일 월요일 오후 1시 40분 EDT에 파이어사이드 채팅 형식으로 발표할 예정입니다.
이 회사는 독자적인 tRNA 합성효소 플랫폼을 통해 혁신적인 약물을 개발하는 데 집중하고 있으며, 발표는 투자자 웹사이트를 통해 웹캐스트로 제공되며, 이후 90일 동안 재생할 수 있습니다. 경영진은 등록된 회의 참석자와 일대일 회의도 진행할 예정입니다.
aTyr는 tRNA 합성효소 생물학을 섬유증 및 염증 치료제로 전환하는 데 전문화되어 있습니다. 그들의 주요 후보인 efzofitimod는 간질성 폐질환 치료를 위해 개발 중인 최초의 생물학적 면역 조절제입니다. 회사의 플랫폼은 20개의 모든 tRNA 합성효소에서 파생된 도메인을 통해 신호 전달 경로를 발견하는 데 중점을 두고 있습니다.
aTyr Pharma (Nasdaq: ATYR), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la Leerink Partners Global Healthcare Conference à Miami, FL, prévue du 9 au 12 mars 2025. Le Dr Sanjay S. Shukla, Président et CEO, présentera sous la forme d'une discussion informelle le lundi 10 mars 2025, à 13h40 EDT.
L'entreprise, qui se concentre sur le développement de médicaments de première classe à partir de sa plateforme propriétaire de tRNA synthétase, rendra la présentation disponible via un webinaire sur son site internet pour les investisseurs, avec un replay accessible pendant 90 jours après. La direction organisera également des réunions individuelles avec les participants enregistrés à la conférence.
aTyr se spécialise dans la traduction de la biologie de la tRNA synthétase en thérapies pour la fibrose et l'inflammation. Leur candidat principal, efzofitimod, est un immunomodulateur biologique de première classe en cours de développement pour le traitement des maladies pulmonaires interstitielles. La plateforme de l'entreprise se concentre sur la découverte de voies de signalisation à travers des domaines dérivés des 20 tRNA synthétases.
aTyr Pharma (Nasdaq: ATYR), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der Leerink Partners Global Healthcare Conference in Miami, FL, die vom 9. bis 12. März 2025 stattfinden soll, bekannt gegeben. Dr. Sanjay S. Shukla, Präsident und CEO, wird am Montag, den 10. März 2025, um 13:40 Uhr EDT in einem informellen Gespräch präsentieren.
Das Unternehmen, das sich auf die Entwicklung von erstklassigen Medikamenten aus seiner proprietären tRNA-Synthetase-Plattform konzentriert, wird die Präsentation über einen Webcast auf seiner Investoren-Website verfügbar machen, mit einer Wiederholung, die 90 Tage lang zugänglich ist. Das Management wird auch Einzelgespräche mit registrierten Konferenzteilnehmern führen.
aTyr spezialisiert sich darauf, die Biologie der tRNA-Synthetase in Therapien für Fibrose und Entzündungen zu übersetzen. Ihr wichtigster Kandidat, efzofitimod, ist ein erstklassiger biologischer Immunmodulator, der zur Behandlung von interstitieller Lungenerkrankung entwickelt wird. Die Plattform des Unternehmens konzentriert sich darauf, Signalwege durch Domänen zu entdecken, die von allen 20 tRNA-Synthetasen abgeleitet sind.
- None.
- None.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 9 – 12, 2025, in Miami, FL.
Details of the presentation appear below:
Conference: Leerink Partners Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 1:40pm EDT
Location: Miami, FL
Format: Fireside Chat
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Sr. Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
FAQ
When and where will aTyr Pharma (ATYR) present at the Leerink Partners Conference 2025?
What is efzofitimod and what is it being developed for by aTyr Pharma?
How long will the replay of aTyr's Leerink conference presentation be available?
What is the focus of aTyr Pharma's discovery platform?
What type of meetings will aTyr management conduct at the Leerink conference?
